[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracerebral-haemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracerebral-haemorrhage":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,46,84,114,151,192,220,253,281,305,325,351,381,402,427,451,477],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100596344","phase-4-nicardipine-for-fast-achievement-of-systolic-bp-targets-in-ich-100596344",false,"NCT07044232","NICardipine for Fast Achievement of Systolic BP Targets in ICH","NICardipine for Fast Achievement of Systolic BP Targets in ICH - a Quasi-randomized, Implementation Trial With Stepwise Rollout of Nicardipin Based Treatment of Hypertension.","NICFAST","Inclusion Criteria:\n\n* Age ≥18 years\n* Acute spontaneous Intracerberal Hemorrhage confirmed by imaging\n* Symptom onset to stroke center admission \\\u003C6 hours\n* Elevated systolic blood pressure (\\>140 mmHg) at admission\n\nExclusion Criteria:\n\n* Secondary causes of ICH (e.g., trauma, vascular malformation)\n* Presumed fatal bleeding at admission\n* Short remaining life expectancy (\\\u003C12 month)","ALL","18 Years",{"count":20,"type":21},88,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Quality improvement study with a quasi-randomized design. The study monitors the effect of a gradually implemented treatment algorithm prioritizing intravenous antihypertensives (e.g., nicardipine) over long-acting nitrate patches. It aims to increase the proportion of patients reaching target systolic BP \\\u003C140 mmHg within 1 hour of hospital admission while monitoring safety, clinical outcomes, and healthcare resource utilization.",[27],"Intracerebral Haemorrhage",[27,29,30,31,32],"blood pressure treatment","acute blood pressure treatment","nicardipine","glyceryl trinitrate","RECRUITING","2026-06-22",{"date":36,"type":37},"2026-06-24","ACTUAL",{"date":39,"type":37},"2025-10-01",{"date":41,"type":21},"2027-09-30",{"name":43,"class":44},"Aarhus University Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100549078","phase-4-international-care-bundle-evaluation-in-cerebral-hemorrhage-research-100549078","NCT06429332","International Care Bundle Evaluation in Cerebral Hemorrhage Research","International Care Bundle Evaluation in Cerebral Hemorrhage Research - a Batched Parallel Cluster-randomized Trial With a Baseline Period","I-CATCHER","Inclusion Criteria:\n\n* Adults (age ≥18 years)\n* Non-contrast computerized tomography (NCCT) imaging-verified diagnosis of spontaneous intracerebral haemorrhage\n* ≤24 hours from symptom onset or presumed symptom onset (last seen well)\n\nExclusion Criteria:\n\n* Previous care limitation\n* End-stage comorbidity with short life-expectancy (\\\u003C6 m; e.g. terminal cancer)\n* ICH caused by brain tumor or cerebral venous thrombosis\n* Clinical signs of brain herniation at first presentation (unresponsive patient with bilaterally fixed, maximally dilated pupils)\n* Pregnant women beyond 22 weeks gestation may only be included after thorough discussion with an obstetrician to determine risks vs benefit.",{"count":55,"type":21},3500,[24],"Spontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality. Approximately half of all patients with ICH have a decreased level of consciousness at hospital admission. Despite this, intensive care and neurosurgical interventions are uncommon. A study conducted in low- and middle-income countries has demonstrated a beneficial effect of a treatment package consisting of early intensive blood pressure lowering, as well as the treatment of pyrexia and elevated blood glucose levels. The I-CATCHER team is now planning to conduct a similar study in Sweden and Australia, as well as in other high-income countries. The study has a clear focus on implementation, aiming to improve treatment and prognosis for patients with ICH within a few years. The purpose of I-CATCHER is to investigate whether a structured treatment package (Care Bundle) improves 3-month prognosis in patients with spontaneous ICH compared to standard care.",[59,27,60,61,62],"Intracerebral Hemorrhage","Intraventricular Hemorrhage","Stroke","Cerebrovascular Disease",[64,65,66,67,68,69,70,71,72,73],"intracerebral hemorrhage","oral anticoagulant","blood pressure lowering","early intensive blood pressure lowering","care bundle","implementation study","reversal treatment","outcome","UW-mRS","Modified Rankin Scale","2026-05-20",{"date":76,"type":37},"2026-05-22",{"date":78,"type":37},"2025-01-07",{"date":80,"type":21},"2027-07",{"name":82,"class":44},"Region Skane",54,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100624830","testing-the-effectiveness-of-a-novel-intervention-to-improve-medication-adherence-in-stroke-survivors-100624830","NCT07414732","Testing the Effectiveness of a Novel Intervention to Improve Medication Adherence in Stroke Survivors","The \"Savvy for Stroke Survivors\" Study: Testing a Novel Tool to Help Stroke Survivors Take Their Medication","Inclusion criteria:\n\n1. Participants must be between the ages of 18 years old and 99 years old at the time of consent.\n2. Self-reported primary diagnosis of stroke (ischemic or hemorrhagic) within the past 12 months, without structural, traumatic or secondary causes (including aneurysm, arteriovenous malformation, or tumor).\n3. Currently prescribed an antihypertensive regimen.\n4. Currently less than optimal adherence to medication, defined as a score \\\u003C25 on the Medication Adherence Report Scale (MARS-5).\n5. Cognitively able to manage medications independently, defined as a score of \\>4 on the Six-Item Screener (SIS) for cognitive impairment.\n6. Speaks English sufficiently to complete consent and study procedures.\n7. Has access to a phone that can receive text messages and is able to participate in scheduled phone-based follow-up assessments.\n8. Uses, or willing to start using, a single pharmacy chain for prescription refills and is willing to provide consent for the study team to contact the pharmacy to retrieve prescription refill data.\n9. Willing and able to provide informed consent.\n\nExclusion criteria:\n\n1. Prescribed a more than three scheduled daily medication doses.\n2. Prescribed a complex medication regimen requiring more than five additional oral medications per dose time.\n3. Diagnosed with secondary hypertension or other BP conditions not managed with standard oral antihypertensives.\n4. Has upper extremity impairments or other physical limitations that prevent safe use of the medication box or BP monitor.\n5. Lives in an environment where the medication organizer cannot be safely or consistently accessed, such as in temporary housing, shelters, or unstable living conditions.\n6. Diagnosed with moderate-to-severe cognitive impairment, dementia, or active psychiatric instability that precludes informed consent or reliable participation.\n7. Known allergy or contraindication to the materials used in the BP monitor or the medication box.\n8. Participation in another intervention trial targeting medication adherence or BP control.\n9. Planned relocation or anticipated unavailability for the 12-month study period.","99 Years",{"count":93,"type":21},150,[95],"NA","The goal of this study is to test if Savvy, a multimodal intervention (consisting of psychological exercises, a weekly pill organizer, and a text message reminder system) can improve medication adherence in stroke survivors.\n\nThe main questions it aims to answer are:\n\n* Can the Savvy tool improve medication adherence in stroke survivors compared to usual care?\n* Does the use of the Savvy tool lead to better blood pressure control after a stroke?\n\nThe investigators will compare the use of the Savvy intervention to a control group that receives usual care, including a package of educational materials.\n\nThe study consists of the following components:\n\n* Participants will receive the Savvy intervention or usual care. The intervention package consists of short psychological exercises over the phone, a weekly medication organizer to support daily medication intake, and text message reminders to take medication and refill the medication box. Participants in the control group will receive usual care, including educational materials about the importance of blood pressure and medication.\n* All participants will receive a free home blood pressure monitor and will be requested to measure their blood pressure at certain time points during the study.\n* Participants will be enrolled in the study for 6 months and will have virtual follow-up calls at 3 and 6 months.",[61,27,98,99],"Ischemic Stroke","TIA (Transient Ischemic Attack)",[101,102,103,61,104],"Medication Adherence","Motivational Interviewing (MI)","Blood pressure","Secondary Prevention","2026-05-19",{"date":74,"type":37},{"date":108,"type":37},"2026-03-31",{"date":110,"type":21},"2027-04-30",{"name":112,"class":44},"Massachusetts General Hospital",2,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":122,"targetDuration":124,"studyType":125,"phases":4,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100635512","master-study-protocol-for-the-cohort-of-the-specialist-network-stroke-sn-strokestroke-core-100635512","NCT07553650","Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)","Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke) (Stroke-CORE)","Stroke-CORE","Inclusion Criteria:\n\n* Diagnosis of AIS or ICH; the AIS diagnosis may be diagnosed clinically or radiologically (i.e., focal neurological impairment of sudden onset, lasting more than 24 hours and of presumed vascular origin, or with proof of cerebral ischaemia corresponding to the clinical symptoms in neuroimaging); for ICH diagnosis requires clinical symptoms and radiological diagnosis of ICH\n* Hospital admission \\\u003C24h after symptom onset\n* Age 18+ years for the basic Modules AIS and ICH; age \\\u003C18 years for the basic Module paediatric stroke patients\n* Informed consent: Signed IC from patients capable of giving consent and understanding all content of the IC or IC of an appropriate patient representative or deferred consent, if patients are unable to consent themselves\n* Additional inclusion criteria are defined by the individual Modules\n\nExclusion Criteria:\n\n* In-hospital stroke\n* TIA\n* SAH\n* Stroke as a complication of a medical procedure\n* Enrolment in a randomised placebo-controlled interventional trial\n* Already enrolled in the SN STROKE base cohort",{"count":123,"type":21},12750,"90 Days","OBSERVATIONAL","The Stroke-CORE cohort aims to provide a comprehensive and up-to-date understanding of stroke care in Germany. To achieve this, patients are followed along the entire continuum of care-from initial management before hospital admission, through acute treatment, rehabilitation, and follow-up care, to the prevention of recurrent strokes. Strokes occurring in childhood are also included in this cohort study.\n\nIn addition, the study seeks to establish effective structures for the early identification and inclusion of patients in clinical research (screening). In this context, structured screening processes are being implemented across all levels of care at participating sites within the Network University Medicine (NUM), a collaboration of German university hospitals. At the same time, the cohort serves as a platform within this network to systematically address open research questions in various areas of stroke care and to support the targeted planning and conduct of future clinical studies.\n\nThe study includes patients with ischemic stroke (caused by a blocked blood vessel) or intracerebral hemorrhage (bleeding within the brain). Participation takes place in different thematic modules, each focusing on specific aspects of the disease course and its management. These modules address, among other topics, acute hospital treatment, measures to prevent recurrent strokes (secondary prevention), possible complications, pre-hospital care, rehabilitation, follow-up care, and long-term outcomes such as physical recovery, independence in daily life, and cognitive functions including memory and concentration.\n\nAs part of the study, a range of data is collected. This includes sociodemographic information (such as age and living situation) as well as medical data, for example on prior conditions, diagnoses, treatments, and comorbidities. In addition, patients' health status is assessed at multiple time points in order to better understand the course of the disease. Depending on the level of participation, data collection may be complemented by the collection of biological samples, such as blood. These are obtained either during routine clinical procedures or through simple, minimally burdensome (non-invasive) methods.\n\nThe study is structured into several levels that differ in the scope and depth of data collection. The basic level includes essential information, while higher levels involve more detailed assessments. In addition, some levels include the collection of biological samples, and there are optional supplementary modules in which patients may participate voluntarily. This tiered approach allows participation to be flexibly adapted to the individual situation while contributing to a nuanced and comprehensive understanding of stroke care.",[27,128,129,61,98],"Paediatric Stroke","Stroke Acute",[61,131,59,128,132,133,134,135,136,137,138,139],"ischemic stroke","Cerebrovascular Disorders","Brain Diseases","Vascular Diseases","Cardiovascular Diseases","Brain Infarction","Embolic Stroke","Thrombotic Stroke","Acute","NOT_YET_RECRUITING","2026-04-23",{"date":143,"type":37},"2026-04-28",{"date":145,"type":21},"2026-05-01",{"date":147,"type":21},"2030-06-30",{"name":149,"class":44},"Charite University, Berlin, Germany",12,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":162,"conditions":163,"keywords":173,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":45},"100597086","phase-1-psychedelic-healing-adjunct-therapy-harnessing-opened-malleability-100597086","NCT07053917","Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","PHATHOM","Inclusion Criteria:\n\n* Over age 18 years, inclusive.\n* Ischemic or hemorrhagic stroke confirmed by CT or MRI, at least 12 months prior to admission date\n* Ability to give informed consent and understand the tasks involved.\n* Agree that, for the study duration, will refrain from: (1) No new prescription medications during the time of the study without approval of the study team, (2) taking any herbal supplement (except with prior approval of the research team), (3) taking any nonprescription medications with the exception of: 1. non-steroidal anti-inflammatory drugs. 2. acetaminophen. 3. vitamins. 4. or other over-the-counter medications approved by the research team\n* Are willing to follow restrictions and guidelines concerning medications, consumption of food, beverages, and nicotine the night before and just prior to psilocybin administration.\n* Agree to have transportation other than driving themselves home or to where the participants are staying after the administration of psilocybin.\n* Are willing to be contacted via telephone for all necessary telephone contacts.\n* Must have a negative pregnancy test if able to bear children.\n* Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal.\n* Must agree to inform the investigators within 48 hours of any new medical conditions and procedures.\n* Are proficient in speaking and reading English.\n* Agree to have all clinical visit sessions recorded to audio and video.\n* Agree to not participate in any other interventional clinical trials during the duration of this study.\n\nExclusion Criteria:\n\n* Taking one of the following medications in the 30 days prior to psilocybin administration:\n\n  1. selective serotonin reuptake inhibitor (SSRI)\n  2. Serotonin-norepinephrine reuptake inhibitors (SNRI)\n  3. Buproprion\n  4. Valproic acid\n  5. Zolpidem\n  6. Trazodone\n  7. Carbamazepine.\n  8. tricyclic antidepressants\n  9. Monoamine Oxidase Inhibitors\n  10. Mirtazapine\n\n  l. Lithium m. Buspirone n. Atypical antipsychotics o. Zolpidem p.Carbamazepine q. Clonazepam r. Gabapentin s. Lamotrigine t. Levetiracetam u. Phenobarbital v. Phenytoin w. Topiramate x. Valproic Acid y. Zonisamide\n* History of medically significant suicide attempt.\n* Evidence of acute cardiac dysfunction as evidenced by either elevated troponin or EKG changes within 48 hours of administration.\n* Systolic blood pressure that is greater than 150 mmHg systolic on \\> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.\n* Diastolic blood pressure that is greater than 100 mmHg systolic on \\> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.\n* Systolic blood pressure is less than 90 mmHg systolic on \\> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.\n* Diastolic blood pressure is less than 30 mmHg systolic on \\> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.\n* Systolic blood pressure exceeds 160 mmHg or is less than 90 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.\n* Diastolic blood pressure exceeds 100 mmHg or is less than 30 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.\n* Cognitive impairment that, in the estimation of the study team, would preclude the use of the MindPod Dolphin.\n* History of physical or neurological condition that interferes with study procedures or assessment of motor function (e.g. severe arthritis, severe neuropathy, Parkinson's disease).\n* Social and\u002For personal circumstances that interfere with ability to perform follow up assessments.\n* Are pregnant or nursing.\n* Weigh less than 48 kg.\n* Are not able to give adequate informed consent.\n* Are actively abusing opioids, cocaine, Phencyclidine (PCP), amphetamines, or alcohol.\n* Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID-5) criteria for moderate or severe substance use disorder\n* Diagnosis of schizophrenia, history of prior psychosis, anxiety requiring hospitalization, or Type 1 bipolar.\n* Hypernatremia\n* Hypokalemia (but can have received repletion during the prior 24 hours)\n* Hyperkalemia\n* Glomerular filtration rate of \\\u003C 30 ml\u002Fmin\n* Elevated of white blood cell count\n* Hemoglobin \\\u003C 7 g\u002Fdl\n* Platelet count \\\u003C 100,000 g\u002Fdl\n* Acute cardiac dysfunction demonstrated by either troponin elevation (chronic elevation is acceptable), or EKG changes suggestive of acute coronary syndrome.\n* Active suicidal ideation as assess by the C-SSRS.",{"count":159,"type":21},20,[161],"PHASE1","The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.",[61,164,27,165,166,98,167,168,169,170,171,172],"Chronic Stroke","Intracerebral Haemorrhage (ICH)","Intracerebral Hemorrhage Basal Ganglia","Ischemic Stroke and Hemorrhagic Stroke","Hemiparesis After Stroke","Hemiplegia Following Ischemic Stroke","Hemiplegia and Hemiparesis","Hemiplegia and\u002For Hemiparesis Following Stroke","Middle Cerebral Artery Stroke",[174,175,176,64,177,178,179,180,181,182],"psychedelic","stroke","chronic stroke","stroke recovery","motor recovery","poststroke recovery","poststroke motor recovery","hemiparesis recovery","psychedelic safety","2026-02-11",{"date":185,"type":37},"2026-02-13",{"date":187,"type":37},"2026-02-09",{"date":189,"type":21},"2027-03",{"name":191,"class":44},"Johns Hopkins University",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":91,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100611678","phase-3-reducing-the-burden-of-cardiovascular-events-with-antiplatelet-therapy-in-patients-with-intracerebral-haemorrhage-100611678","NCT07243704","Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage","Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage.","BEAT-ICH","Inclusion Criteria:\n\n* Age ≥18 years\n* First-ever Intracerebral Haemorrhage\n* Presenting ≥24 hrs up to 3 months of stroke symptoms confirmed by brain imaging\n* CT \u002FMRI confirming Intracerebral Haemorrhage\n* Alive ≥24 hours after non-traumatic ICH\n\nExclusion Criteria:\n\n* ICH is known to be due to trauma, a structural cause (e.g., aneurysm, arteriovenous malformation, cerebral cavernous malformation, venous thrombosis, or tumour), or haemorrhagic transformation of cerebral infarction\n* Glasgow coma score ≤5\n* Taking any antiplatelet or anticoagulant therapy 15 days prior to randomization.\n* Women pregnant, breastfeeding, childbearing potential, and not using contraceptives\n* Enrolled in any other clinical trial\n* Sick or compromised patients with life expectancy of less than a year\n* Geographical or other factors that prohibit long-term follow-up",{"count":201,"type":21},5676,[203],"PHASE3","BEAT ICH will be a pragmatic, randomised, placebo-controlled, blinded, superiority clinical trial aiming to recruit 5676 patients aged ≥18 years who survive ICH and assign them 1:1 to starting antiplatelet monotherapy (Aspirin 75 mg od) versus placebo for the entire duration of the trial for preventing MACE. Recruitment duration is for 2.5 years. The duration of the medication and follow-up will vary based on recruitment timeline. If recruited during the first year of the trial, the patient will take the medication for three years or until the trial ends or an event occurs, with a matching follow-up period. If recruited towards the end of the trial, he\u002Fshe will take the medication for six months and be followed up for the same duration. The trial's follow-up duration is three years. The patients will be recruited for 2.5 years, and the last recruit will have a minimum follow-up of six months. No new patients will be recruited within the last six months of the trial, but all the patients will be followed up until the end of the trial.",[27],[175,27,207,208,209,104,210],"antiplatelet","Major adverse cardiovascular and cerebrovascular events","Randomized control trial","Recurrent stroke","2026-02-05",{"date":187,"type":37},{"date":214,"type":21},"2026-02-15",{"date":216,"type":21},"2029-02-14",{"name":218,"class":44},"Christian Medical College and Hospital, Ludhiana, India",40,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":229,"conditions":230,"keywords":231,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":45},"100617468","ai-assisted-transcranial-duplex-sonography-for-early-detection-of-intracerebral-haemorrhage-hyper-ai-scan-100617468","NCT07319013","AI-assisted Transcranial Duplex Sonography for Early Detection of Intracerebral Haemorrhage: HYPER-AI-SCAN","HYPER-AI-SCAN: HYPER-acute AI-assisted Sonographic Cerebral Hemorrhage Assessment Network","Inclusion Criteria:\n\n* Adult patients (age ≥18 years).\n* Clinical diagnosis of acute stroke (ischemic or intracerebral hemorrhage).\n* Able to undergo transtemporal transcranial ultrasound according to the standardized protocol (no clinical instability)\n* Informed consent obtained from the patient or legally authorized representative, per local regulations.\n\nExclusion Criteria:\n\n* Infratentorial hemorrhage (e.g., cerebellar or brainstem hemorrhage), due to limitations of transtemporal insonation.\n* Isolated subarachnoid hemorrhage without parenchymal involvement.\n* Hemodynamic instability or medical conditions requiring immediate life-saving intervention that preclude safe ultrasound recording.\n* Known skull defects or prior craniectomy on the side required for contralateral insonation.\n* Any condition that, in the opinion of the investigators, would interfere with protocol adherence or data accuracy.",{"count":228,"type":21},500,"The goal of this observational study is to evaluate whether transcranial Doppler ultrasound, combined with artificial intelligence (AI), can help identify intracerebral haemorrhage (ICH) in people with acute stroke (both men and women, adults of all ages) within 48 hours of symptom onset.\n\nThe main questions it aims to answer are:\n\nIs it feasible to perform standardized protocol transcranial ultrasound in acute stroke patients? Can AI models trained on ultrasound images accurately distinguish haemorrhagic stroke (\"ICH suspected\") from non-haemorrhagic stroke? There is no comparison group, because all participants will undergo both CT (as standard care) and ultrasound (research imaging), and the AI models will compare their ultrasound-based predictions against CT-confirmed diagnoses.\n\nParticipants will:\n\nundergo a non-invasive transcranial ultrasound scan after CT confirms the type of stroke allow researchers to collect coded ultrasound images for AI model training provide clinical and imaging information (already collected as part of routine care) to help evaluate factors related to diagnostic accuracy No treatments or changes to clinical care will be introduced as part of the study.",[61,59,166,27],[175,232,98,233,234,235,236,237,238,239,240,241,242,243],"intracerebral hemorrage","Hemorrhagic Stroke","transcranial ultrasound","Transcranial Doppler","Portable Ultrasound","Neurosonology","Artificial Intelligence","Machine Learning","Diagnostic Accuracy","Prehospital Care","Feasibility Study","Deep Learning","2025-12-19",{"date":246,"type":37},"2026-01-06",{"date":248,"type":37},"2025-03-14",{"date":250,"type":21},"2027-06",{"name":252,"class":44},"Hospital Universitari Vall d'Hebron Research Institute",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":113},"100608941","stereotactic-thrombolysis-with-tenecteplase-for-supratentorial-intracerebral-hemorrhage-100608941","NCT07208097","Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage","STEPS","Inclusion Criteria ：\n\n1. . Age 18 to 80 years, any gender.\n2. . Clinically confirmed acute spontaneous supratentorial intracerebral hemorrhage (ICH), with diagnostic CT completed within 24 hours of symptom onset (for patients with unknown time of onset or wake-up stroke, the time from the last known well to symptom detection is used as the presumed onset time).\n3. . CT-confirmed supratentorial ICH with hematoma volume calculated by ABC\u002F2 method between 25 mL and 60 mL (inclusive).\n4. . National Institutes of Health Stroke Scale (NIHSS) score ≥ 6.\n5. .Glasgow Coma Scale (GCS) score between 9 and 14 (inclusive).\n6. . Pre-stroke modified Rankin Scale (mRS) score ≤ 1.\n7. . Good compliance, with written informed consent provided by the patient and\u002For legal guardian, and ability to adhere to the scheduled follow-up visits.\n\nExclusion Criteria：\n\n1. . Brainstem or cerebellar hemorrhage; or thalamic hemorrhage with significant midbrain shift accompanied by third nerve palsy or unreactive dilated pupils.\n2. . Irreversible brainstem dysfunction (bilateral fixed, dilated pupils and decerebrate posturing).\n3. . Secondary ICH caused by: head trauma, arteriovenous malformation (AVM), moyamoya disease, intracranial aneurysm, coagulation disorders (hereditary or acquired hemorrhagic diathesis, hemophilia, coagulation factor deficiency, leukemia, etc.), hemorrhagic transformation of cerebral infarction, or tumor; multiple intracranial hemorrhages, subarachnoid hemorrhage (SAH), primary intraventricular hemorrhage, drug-induced hemorrhagic stroke, subdural hemorrhage, epidural hemorrhage.\n4. . Significant abnormalities in the following laboratory parameters:(1)International normalized ratio (INR) \\> 1.4; any irreversible coagulopathy or known coagulation disorder that cannot be corrected with procoagulants to maintain INR ≤ 1.4. (2) Severe hepatic insufficiency: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 3 times the upper limit of normal (ULN). (3) Severe renal insufficiency: estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73m². (4)Hemoglobin \\\u003C 90 g\u002FL.5）Platelet count \\\u003C 100 × 10⁹\u002FL.\n5. . History of malignancy, autoimmune diseases (including but not limited to systemic lupus erythematosus, systemic vasculitis), hemorrhagic diathesis (including various hereditary and acquired bleeding disorders), malignant arrhythmias, cardiac insufficiency (B-type natriuretic peptide \\[BNP\\] ≥ 1000 pg\u002FmL or left ventricular ejection fraction \\[LVEF\\] ≤ 40%), acute myocardial infarction, acute or severe infectious diseases (e.g., intracranial infection, severe pneumonia, sepsis), or any other severe concurrent illness that may exacerbate the condition or interfere with efficacy assessment.\n6. . Known high risk of thromboembolism, including: presence of a mechanical heart valve prosthesis, history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. (Note: Atrial fibrillation without mitral stenosis is permitted).\n7. . Myocardial infarction within 30 days prior to randomization.\n8. .Use of anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, apixaban) within 1 week prior to symptom onset.\n9. . History of internal bleeding (e.g., gastrointestinal bleeding, genitourinary bleeding, retroperitoneal bleeding) within 3 months prior to randomization.\n10. . Major surgery or vascular puncture (e.g., venesection, arterial puncture) within 3 months prior to randomization.\n11. . History of significant head trauma or severe stroke within 3 months prior to randomization.\n12. . History of intracerebral hemorrhage within 1 year prior to randomization.\n13. . Indications for craniotomy: (1) Progressive impairment of consciousness; (2)Preoperative signs of brain herniation (e.g., foramen magnum herniation, tentorial herniation) posing a life-threatening condition.\n14. . Intraventricular hemorrhage (IVH) or ICH with rupture into the ventricle causing intraventricular cast formation and\u002For hydrocephalus anticipated to require external ventricular drainage (EVD).\n15. . Patient or family requests craniotomy or neuroendoscopic surgery for hematoma evacuation.\n16. . Pre-randomization decision by patient\u002Ffamily for Do-Not-Resuscitate (DNR) or Do-Not-Intubate (DNI) orders regarding life-sustaining measures.\n17. . Known hypersensitivity or intolerance to TNK.\n18. . Pregnancy (positive urine pregnancy test) in women of childbearing potential.\n19. . Concurrent participation in another investigational drug or device study.\n20. . History of drug or alcohol abuse\u002Fdependence, severe dementia, or psychiatric disorder prior to randomization, anticipated to result in poor compliance and inability to complete follow-up.","80 Years",{"count":262,"type":21},768,[95],"This is an phase III prospective, multi-center, open-label, randomized controlled trial (RCT) with blinded endpoint assessment. It plans to enroll 768 subjects with spontaneous supratentorial intracerebral hemorrhage, who will be randomly assigned in a 1:1 ratio to the investigational arm (stereotactic minimally invasive puncture for intracerebral hemorrhage combined with TNK liquefaction drainage, single TNK dose of 0.5mg per time or the standard medical treatment group.",[27,266],"Minimally Invasive Treatment",[268,269,270,271],"intracerebral haemorrhage","minimally invasive treatment","hematoma evacuation","tenecteplase","2025-11-27",{"date":274,"type":37},"2025-12-01",{"date":276,"type":37},"2025-10-25",{"date":278,"type":21},"2028-06-30",{"name":280,"class":44},"Tongji Hospital",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":260,"enrollmentInfo":289,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":291,"conditions":292,"keywords":293,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":45},"100611005","minimally-invasive-surgery-for-patients-with-spontaneous-deep-intracerebral-hemorrhage-100611005","NCT07234955","Minimally Invasive Surgery For Patients With Spontaneous Deep Intracerebral Hemorrhage","Evaluation Of The Efficacy And Safety Of Minimally Invasive Surgery In Patients With Spontaneous Deep Intracerebral Hemorrhage","MISDIH","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Spontaneous basal ganglia intracerebral hemorrhage confirmed by non-contrast CT scan\n* Hematoma volume 30-80 mL (ABC\u002F2 method)\n* Time from onset\u002Flast known well ≤ 72 hours\n* Glasgow Coma Scale (GCS) score 5-14 at admission\n* Pre-stroke modified Rankin Scale (mRS) score 0-1\n\nExclusion Criteria:\n\n* Secondary intracerebral hemorrhage due to trauma, tumor, vascular malformation, aneurysm, or hemorrhagic transformation of ischemic stroke\n* Infratentorial hemorrhage (brainstem or cerebellum)\n* Primary thalamic hemorrhage\n* Extensive intraventricular hemorrhage (\\>50% of one lateral ventricle)\n* NIHSS \\\u003C 5 at admission\n* Bilateral fixed dilated pupils without light reflex\n* Decerebrate posture\n* Platelet count \\\u003C 75,000\u002FµL\n* INR \\> 1.4 after correction\n* Ongoing anticoagulation that cannot be rapidly reversed\n* Indication for long-term anticoagulation within 5 days of onset\n* End-stage renal disease\n* End-stage liver disease\n* Presence of mechanical heart valve\n* Any comorbidity with life expectancy \\\u003C 6 months\n* Patient or legal representative unwilling or unable to provide written informed consent",{"count":290,"type":21},300,"This observational cohort study evaluates the safety and effectiveness of minimally invasive surgery (MIS) compared with standard medical management in adults with spontaneous deep intracerebral hemorrhage. Consecutive patients admitted to People's Hospital 115 and Tam Anh General Hospital will be enrolled within 72 hours of onset. Clinical and imaging data will be collected prospectively, and outcomes including survival and functional status will be assessed through 180 days.",[166,27],[294],"Deep Intracerebral Hemorrhage","2025-11-14",{"date":297,"type":37},"2025-11-19",{"date":299,"type":37},"2025-09-08",{"date":301,"type":21},"2028-09-01",{"name":303,"class":304},"Huynh Quoc Huy","OTHER_GOV",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":260,"enrollmentInfo":312,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":313,"conditions":314,"keywords":315,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":45},"100605717","timing-and-outcomes-of-recovery-after-intracerebral-hemorrhage-100605717","NCT07166146","Timing and Outcomes of Recovery After intraCerebral Hemorrhage","TORCH","Inclusion Criteria:\n\n* Subject Age is ≥18 to ≤80 years\n* Subject with a Head CT\u002FCTA that demonstrates an acute, spontaneous, primary, supratentorial ICH, assessed via standard of care techniques\n* Subject recieving a surgery intervention\n* Subject has a NIHSS score ≥ 6 or GCS score 5≤GCS≤15\n* Subject has a baseline Modified Rankin Scale (mRS) Score ≤ 1\n\nExclusion Criteria:\n\n* Secondary intracerebral hemorrhage (with leading cause, e.g., Moyamoya disease, arteriovenous malformation, intracranial aneurysm, tumor, brain trauma)\n* Pre-stroke life expectancy \\\u003C 1 year for severe comorbidities (e.g., Progressive malignant tumor, severe chronic heart failure \\[NYHA: III-IV\\], severe chronic obstructive pulmonary disease \\[III-IV\\], chronic kidney disease requiring hemodialysis)\n* Patients with platelet count \\\u003C 100,000, INR \\> 1.4, or an elevated PT or APTT (reversal of coumadin is permitted but the patient must not require coumadin during the acute hospitalization). Irreversible coagulopathy either due to medical condition or prior to randomization\n* Pregnant (positive pregnancy test) or lactating females (likelihood of altered coagulation function associated with the high estrogen\u002Fprogesterone state)\n* Irreversibly impaired brainstem function (bilateral fixed, dilated pupils and extensor motor posturing), GCS less than or equal to 4",{"count":228,"type":21},"The TORCH registry is a prospective, observational cohort study, which will collect detailed, longitudinal data on the clinical characteristics, treatment modalities, and outcomes of patients with ICH. By leveraging a wide array of surgical interventions - including endoscopic surgery, minimally invasive surgery combined with urokinase, and craniotomy - the TORCH registry intends to provide a granular view of early hematoma evacuation surgical interventions and their impact on patient recovery and quality of life.",[27,59],[27,59],"2025-09-02",{"date":318,"type":37},"2025-09-10",{"date":320,"type":37},"2025-06-04",{"date":322,"type":21},"2028-03-15",{"name":324,"class":44},"Xuanwu Hospital, Beijing",{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":332,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":334,"conditions":335,"keywords":338,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":113},"100417200","the-ebc-recovery-study-100417200","NCT04712591","The EBC Recovery Study","Electrophysiologic Biomarkers of Consciousness (EBC) Recovery After Brain Injury","Inclusion Criteria:\n\nFor ABI Participants\n\n* ABI adult (18 years and older) patients who are admitted to the intensive care unit\n* Unconscious with Glasgow Coma Scale (GCS) \\<8 on presentation and unable to follow bedside commands.\n* A negative COVID-19 test on arrival\n\nFor Healthy Volunteers:\n\n* 18 years and older\n\nExclusion Criteria:\n\nFor All Participants:\n\n* \\<18 years of age\n* Pregnant woman\n* Patients with cardiac arrest on presentation",true,{"count":290,"type":21},"The purpose of this research study to find out if clinically unconscious acute brain injury patients that show brain activation to music and language on electroencephalogram (EEG) (bedside test) have better outcomes and wake up in the future.",[336,27,337],"Traumatic Brain Injury","Subarachnoid Haemorrhagic Stroke",[339,340,341,342],"Consciousness","Coma","Recovery","Electroencephalogram",{"date":344,"type":37},"2025-09-04",{"date":346,"type":37},"2020-06-18",{"date":348,"type":21},"2030-01-01",{"name":350,"class":44},"University of Miami",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":260,"enrollmentInfo":359,"targetDuration":4,"studyType":22,"phases":361,"briefSummary":362,"conditions":363,"keywords":366,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":380},"100599727","statins-for-treatment-of-primary-intracerebral-hemorrhage-100599727","NCT07088250","Statins for Treatment of Primary Intracerebral Hemorrhage","Statins for Treatment Of Primary IntraCerebral Hemorrhage (STOP ICH)","STOP ICH","Inclusion Criteria:\n\n* Patients with a diagnosis of spontaneous intracerebral hemorrhage (ICH) confirmed by computed tomography (CT);\n* Age 18-80 years;\n* Hematoma located in the supratentorial region;\n* Time from symptom onset or last known well to baseline CT ranging from 3 to 24 hours;\n* Atorvastatin treatment can be initiated within 48 hours of symptom onset or last known well;\n* Glasgow Coma Scale (GCS) score ≥9;\n* Baseline hematoma volume of 5-35 mL;\n* Signed informed consent obtained.\n\nExclusion Criteria:\n\n* ICH secondary to trauma, tumor, aneurysm, arteriovenous malformation (AVM), vascular anomaly, hemorrhagic transformation of infarction, cerebral venous thrombosis, or anticoagulant-related ICH;\n* Patients who have undergone or are scheduled for immediate surgical intervention;\n* Pregnancy or lactation;\n* Use of oral anticoagulants within 1 month prior to symptom onset;\n* Pre-stroke mRS \\>1;\n* Known allergy to statins, active liver disease, liver dysfunction, or rhabdomyolysis;\n* Known terminal illness with a pre-stroke life expectancy of less than three months, or patients with planned withdrawal of care.",{"count":360,"type":21},264,[95],"The STOP ICH trial is a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study designed to assess the efficacy and safety of atorvastatin in patients with intracerebral hemorrhage (ICH) presenting within 3 to 24 hours of symptom onset.",[132,364,365,27],"Intracranial Hemorrhages","Intracranial Hemorrhage",[367,368,369,370],"Intracerebral hemorrhage","Treatment","Atorvastatin","Outcome","2025-07-20",{"date":373,"type":37},"2025-07-28",{"date":375,"type":37},"2023-05-06",{"date":377,"type":21},"2026-12-31",{"name":379,"class":44},"The Second Hospital of Anhui Medical University",22,{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":45},"100467636","phase-2-efficacy-and-safety-of-mirabegron-in-intracerebral-hemorrhage-100467636","NCT05369351","Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage","Inclusion Criteria:\n\n1. Male or female patients aged above 18 years old.\n2. The volume of the hematoma is 5-30 ml (including the cerebral cortex; Putamen, thalamus, caudate nucleus and related deep tracts; Cerebellar hemorrhage), which determined by CT scan.\n3. The onset of cerebral hemorrhage symptoms or the time from last normal to detection is not more than 72 hours.\n4. Patients with Glasgow Coma Scale (GCS) score ≥6 and \\\u003C 12.\n5. Before the onset of the disease, function was independent and mRS score\\\u003C1.\n6. Able and willing to sign written informed consent and comply with the requirements of the research protocol.\n\nExclusion criteria:\n\n1. Multifocal cerebral hemorrhage, brain stem hemorrhage, or ventricular hemorrhage.\n2. Secondary cerebral hemorrhage caused by aneurysm, brain tumor, arteriovenous malformation, thrombocytopenia, coagulation disorder, traumatic brain injury, etc.\n3. Patients who require hematoma removal surgery or other emergency surgical interventions (such as decompressive craniectomy), or who are critically ill and close to death.\n4. Patients who interfere with drug use due to nausea or vomiting.\n5. Combined with the following conditions that preclude participation in the study due to other systemic diseases: Severe hepatic or renal impairment, atrial fibrillation or tachycardia, pulmonary infection, severe urinary tract infection, severe urinary tract obstruction, medically uncontrolled hypertension (systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg), pregnant and lactating women, and a history of malignant tumors within 5 years.",{"count":388,"type":21},25,[390],"PHASE2","Intracerebral hemorrhage (ICH) accounts for 10-15% of all strokes without effective pharmacological treatment. Inflammation following ICH contributes to barrier disruption and peri-hematoma edema, leading to deterioration of neurological function. Preclinical evidence suggests that bone marrow hematopoietic stem and progenitor cells (HSPCs) are swiftly activated after ICH. Thereafter, these HSPCs produce an increased output of anti-inflammatory monocytes as an endogenous protective mechanism. Stimulation of β3 adrenergic receptor using selective agonists promotes the production of anti-inflammatory monocytes in bone marrow, and thereby reduces neuroinflammation, brain edema and neurological deficits. This study is to assess the safety and efficacy of a β3 adrenergic receptor agonist Mirabegron as a potential treatment option in ICH patients.",[27],"2025-05-25",{"date":395,"type":37},"2025-05-28",{"date":397,"type":37},"2024-01-17",{"date":399,"type":21},"2026-11-10",{"name":401,"class":44},"Tianjin Medical University General Hospital",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":260,"enrollmentInfo":410,"targetDuration":4,"studyType":22,"phases":412,"briefSummary":413,"conditions":414,"keywords":415,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":113},"100584828","efficacy-and-safety-of-neuroendoscopic-surgery-for-large-intracerebral-hemorrhage-100584828","NCT06894433","Efficacy and Safety of NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage","Efficacy and Safety of NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage: a Multicenter, Randomized, Controlled Clinical Trial","NESICH 2","Inclusion Criteria:\n\n1. Age 18-80 years old, male or female;\n2. The time between onset and admission to the first diagnostic CT is within 24 hours (for no bystanders and the time of onset is unknown, the time of the last known patient in good condition is used);\n3. Patients with supratentorial intracerebral hemorrhage (supratentorial intracerebral hemorrhage (supratentorial intracerebral hemorrhage) whose hematoma volume is ≥50ml or whose hematoma produces obvious space occupying effect and requires emergency surgery (including patients with cerebral hernia signs such as retarding or dilatation of light reflex of one pupil);\n4. Before randomization, GCS score was 5-14, NIHSS score was ≥6;\n5. mRS Before onset: 0-1 score;\n6. Randomization within 24 hours after the first diagnostic CT;\n7. The patient or family members are informed and voluntarily sign the informed consent;\n\nExclusion Criteria:\n\n1. The clinical diagnosis is caused by cerebral aneurysm, cerebrovascular malformation, moyamoya disease, brain trauma, brain tumor, massive cerebral infarction hemorrhage transformation, coagulation dysfunction, etc.;\n2. Thalamic hemorrhage, primary ventricular hemorrhage;\n3. Platelet count \\\u003C100×109\u002FL, INR \\> 1.4;\n4. Patients with advanced cerebral hernia (such as dilated bifidus and no light reflex) or unstable vital signs cannot tolerate surgery;\n5. Irreversible brain stem impairment (eye fixation, bilateral pupil dilation), GCS≤4 points;\n6. Any history of parenchyma or other intracranial subarachnoid, subdural or epidural blood and surgical history in the past 30 days;\n7. Patients with severe advanced cognitive impairment (such as AD) or who are not expected to complete the follow-up plan as required;\n8. Complicated with other serious diseases: including respiratory, circulation, digestion, urinary, endocrine, immune and blood systems;\n9. Pregnant or breastfeeding women, or those who expect to become pregnant within one year;\n10. are participating in other clinical trials (excluding: observational studies that do not involve intervention, natural history and\u002For epidemiological studies).",{"count":411,"type":21},280,[95],"This is a multicenter, randomized, controlled clinical trial comparing neuroendoscopic hematoma removal to craniotomy in the treatment of large intracerebral hemorrhage.",[27],[64,416,417],"neuroendoscopic","craniotomy","2025-05-14",{"date":420,"type":37},"2025-05-18",{"date":422,"type":21},"2025-06-01",{"date":424,"type":21},"2028-12-31",{"name":426,"class":44},"Southwest Hospital, China",{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":449,"locationsCount":4},"100572321","the-planetary-outcomes-after-intracranial-haemorrhage-study-100572321","NCT06731751","The Planetary Outcomes After Intracranial Haemorrhage Study","A Prospective, International Observational Study Assessing the Global Variation in Patient Characteristics, Management and Outcomes of Spontaneous Intracranial Haemorrhage.","PLOT-ICH","Inclusion Criteria:\n\n* Patients of any age with the presence of spontaneous intracranial haemorrhage (parenchymal, intraventricular and \u002F or subarachnoid haemorrhage) on intracranial imaging (and absence of a history of trauma).\n\nAND:\n\n• Admission to hospital for sICH management. This includes admission for observation, conservative or interventional management to both ward-based and critical care settings.\n\nExclusion Criteria:\n\n* Patients who have a clear history of trauma as the primary cause of the haemorrhage and therefore are diagnosed with traumatic intracranial haemorrhage.\n* Patients with subdural or extradural haematomas but no clear history of trauma.\n* Patients with intracranial haemorrhage occurring as a complication of a procedure or intervention (e.g. post-operative haematoma) or iatrogenic (e.g. after thrombolysis for ischaemic stroke).\n* Patients who undergo elective (planned admission to hospital) or semi-elective (where a patient was initially admitted to hospital, then discharged from hospital and re-admitted for surgery) procedures.\n* Patients re-admitted to hospital within 30 days of the initial admission with sICH (including those re-admitted for acute management of sICH-related complications).\n* Patient presenting to the emergency department (ED) but discharged home from the ED immediately without a period of observation or admission to a ward.",{"count":436,"type":21},1000,"Over twelve million strokes occur worldwide every year, and stroke is the second most common cause of death globally. Strokes happen because blood supply to the brain is damaged. This can be due to a blockage (ischaemic stroke) or a bleed (haemorrhagic stroke - or intracranial haemorrhage). Intracranial haemorrhage can be life-threatening and patients with this type of stroke can be very sick, requiring urgent medical care including medications, close monitoring, and sometimes surgery.\n\nStrokes happen worldwide, but over 80% of stroke cases and associated death and disability occur in low- and middle- income countries (LMICs), where resources to manage them can be limited. However, the differences in how patients present, the hospital care they receive, and their overall outcomes when compared to high-income countries (HICs) patients are not fully understood. There are many stroke-related deaths occurring each year around the world, especially among those who have presented with an intracranial haemorrhage, and if survival rates are to be improved, high-quality data is needed to help us better understand where the improvements in care are required in different health settings.\n\nRun and funded by the University of Cambridge, this study will collect data on all patients across all ages during a one-month period who undergo treatment for spontaneous intracranial haemorrhage, both medical and surgical. We will include patients from any hospital across the world that treats patients with this condition, collecting data from their admission to hospital until their discharge, death or up to 30 days from their presentation.\n\nThis is an observational study, so we are only observing patients care and management, not making any direct changes to their treatment. We will also be asking each centre to complete a written survey, to better understand some of the more complex areas which are important for the care of intracranial haemorrhage patients such as hospital resources available, and the potential barriers they face in accessing appropriate healthcare.",[61,27,439],"Subarachnoid Haemorrhage (SAH)",[441,268,442],"brain haemorrhage","subarachnoid haemorrhage","2024-12-09",{"date":445,"type":37},"2024-12-12",{"date":447,"type":21},"2025-01-01",{"date":377,"type":21},{"name":450,"class":44},"University of Cambridge",{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":459,"enrollmentInfo":460,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":462,"conditions":463,"keywords":464,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":45},"100547615","ischaemic-lesions-in-acute-intracerebral-haemorrhage-100547615","NCT06410274","Ischaemic Lesions in Acute Intracerebral Haemorrhage","Ischaemic Lesions in Acute Intracerebral Haemorrhage: Pathophysiological Investigation Using Novel Multimodal Cerebral and Systemic Haemodynamic Assessments","CHALLENGE-ICH","Inclusion Criteria:\n\n* Clinical diagnosis of a haemorrhagic stroke on CT imaging within 48 hours of onset (for patients waking with a stroke, time of onset will be taken to be the time when the patient was last asymptomatic).\n* Male or female, aged 18 years or above.\n\nExclusion Criteria:\n\n* MRI imaging is contraindicated or unlikely to tolerate scanning process due to clinical instability (GCS \\\u003C8, unable to lie supine).\n* Patients requiring anaesthesia.\n* Male or Female, aged under 18 years.\n* Clinical diagnosis of stroke greater than 48 hours from onset","120 Years",{"count":461,"type":21},120,"The aim of this observational study is to determine how and why inadequate brain blood flow occurs after bleeding in patients with intracerebral haemorrhage (ICH). Treatment for strokes caused by burst blood vessels involves reducing blood pressure (BP) to stop the bleeding. However, this reduction in BP may affect blood flow, causing blockages in blood vessels within the brain. Fast breathing also affects brain blood flow. Therefore, participants will be asked to undergo a simple brain blood flow assessment using transcranial Doppler (TCD) within 48 hours upon admission to hospital. Patients will then have a follow-up TCD assessment at 4-7 days post-ICH onset, in addition to an MRI scan at \\>7 days. This research will help to confirm if blockages after bleeding are caused by reduced blood flow within the brain.",[27],[61,465,466,235,467],"Cerebral Autoregulation","Cerebral Blood Flow","Magnetic Resonance Imaging","2024-09-17",{"date":470,"type":37},"2024-09-19",{"date":472,"type":37},"2024-06-01",{"date":474,"type":21},"2029-01-31",{"name":476,"class":44},"University of Leicester",{"id":478,"slug":479,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":485,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":491,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":510},"100491658","early-minimally-invasive-image-guided-endoscopic-evacuation-of-intracerebral-haemorrhage-eminent-ich-100491658","NCT05681988","Early Minimally Invasive Image Guided Endoscopic Evacuation of Intracerebral Haemorrhage (EMINENT-ICH)","Early Minimally Invasive Image Guided Endoscopic Evacuation of Intracerebral Haemorrhage (EMINENT-ICH): a Randomized Controlled Trial","EMINENT-ICH","Inclusion Criteria:\n\n* Spontaneous supratentorial intracerebral hemorrhage (SSICH), defined as the sudden occurrence of bleeding into the lobar parenchyma and\u002For into the basal ganglia and\u002For thalamus that may extend into the ventricles confirmed by imaging\n* SSICH volume ≥20 mL \\\u003C100 mL\n* A focal neurological deficit consisting of either\n\n  * clinically relevant hemiparesis (≥4 motor points on the NIHSS for facial palsy, motoric upper and lower extremities combined)\n  * clinically relevant motor or sensory aphasia (≥2 points on the NIHSS)\n  * clinically relevant hemi-inattention (formerly neglect, 2 points on the NIHSS)\n  * decreased level of consciousness (Glasgow Coma Scale (GCS)≤13)\n* Presenting GCS 5 - 15 (in intubated patients GCS assessment will be performed after Rutledge et al. or if impossible, the last pre-intubation GCS will be used)\n* Endoscopic hematoma evacuation can be initiated within 24 hours after the patient was last seen well\u002Fsymptom onset\n* Informed consent of patient or appropriate surrogate (for patients without competence)\n\nExclusion Criteria:\n\n* SSICH due to known or suspected structural abnormality in the brain (e.g. vascular malformation, aneurysm, arteriovenous malformation (AVM), brain tumor) and\u002For brain trauma and\u002For hemorrhagic conversion of an ischemic infarction\n* Multiple simultaneous intracranial hemorrhages (ICH) (e.g. multifocal ICH, chronic subdural hematoma (cSDH), acute subdural hematoma (aSDH), SAH)\n* Infratentorial hemorrhage or midbrain extension\u002Finvolvement of the hemorrhage\n* Coagulation disorder (including anticoagulation) with an international normalized ratio (INR) of \\>1.5 which cannot be pharmacologically reverted until the planned time of evacuation\n* Pregnancy\n* Relevant disability prior to SSICH (mRS \\>2)\n* Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 180 days (e.g. bilateral fixed dilated pupils)","85 Years",{"count":487,"type":21},200,[95],"This is an open-labelled, single centre randomised controlled trial evaluating the efficacy of early minimally invasive image-guided hematoma evacuation in combination with the current best medical treatment compared to best medical treatment alone in improving functional outcome rates at 6 months after initial treatment in patients with spontaneous supratentorial intracerebral haemorrhage.",[27],[492,493,494,495,496,497,498,499,500],"spontaneous supratentorial intracerebral haemorrhage (SSICH)","best medical treatment (BMT)","surgical hematoma evacuation","conventional craniotomy (CC)","early image-guided endoscopic surgery","endoscopic surgery (ES)","minimally invasive surgery (MIS)","minimally invasive puncture surgery (MIPS)","stereotactic aspiration (SA)","2024-07-19",{"date":503,"type":37},"2024-07-22",{"date":505,"type":37},"2024-01-01",{"date":507,"type":21},"2029-12",{"name":509,"class":44},"University Hospital, Basel, Switzerland",10]